SCHEMBL234750

SCHEMBL234750

CC(=O)Oc1cccc(-c2cc3cnc4cc(C)nn4c3nc2Br)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.41
GAPDH P04406 2/20 0.41
CYP1A2 P05177 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
LMNA P02545 3/20 0.36
ADORA2A P29274 1/20 0.36
HSD17B10 Q99714 2/20 0.36
ALDH1A1 P00352 3/20 0.35
MAPT P10636 1/20 0.35
FYN P06241 1/20 0.35
KDR P35968 1/20 0.35
PIK3CA P42336 1/20 0.35
AURKA O14965 1/20 0.34
F2RL3 Q96RI0 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238654 0.88 MAOB (0.41) MAOBGAPDHCYP1A2SMN1; SMN2KDM4E
SCHEMBL234670 0.82 FYN (0.40) SMN1; SMN2NPC1RAB9AFYNKDR
SCHEMBL2755334 0.77 NPC1 (0.43) MAOBGAPDHCYP1A2SMN1; SMN2KDM4E
SCHEMBL236382 0.73 FYN (0.38) CYP1A2SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL238176 0.72 MAOB (0.40) MAOBCYP1A2SMN1; SMN2KDM4ENPC1
SCHEMBL238551 0.70 NPC1 (0.41) SMN1; SMN2NPC1RAB9AFYNKDR
SCHEMBL238620 0.69 NPC1 (0.43) SMN1; SMN2KDM4ENPC1RAB9AADORA2A
SCHEMBL239031 0.69 NPC1 (0.51) SMN1; SMN2NPC1RAB9ALMNAADORA2A
SCHEMBL2755336 0.68 AKT1 (0.40)
SCHEMBL235881 0.67 RAB9A (0.48) SMN1; SMN2KDM4ENPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 MAOB 3293/4885GAPDH 2308/4885CYP1A2 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.